Topical Drugs CDMO Market - By Product Type, Therapeutic Area, Service Type, End-user, Global Forecast

Description

Global Topical Drugs CDMO Market will witness over 12.1% CAGR from 2024 to 2032, spurred by the strengthening consumer preference for over-the-counter products. As consumers seek convenient and cost-effective healthcare solutions, the demand for OTC topical treatments, such as creams and ointments, is rising. This trend is supported by the increasing availability of these products in retail and online pharmacies.

CDMOs benefit from this shift as pharmaceutical companies outsource the development and manufacturing of OTC products to meet demand. Consequently, the focus on self-care and easy access to OTC medications continue to bolster the CDMO market for topical drugs. A recent grocery doppio survey reveals that 70% of consumers have tried private-label products, with 50% planning to continue purchasing them into 2024. This trend indicates a growing shift towards private labels in the retail market.

The topical drugs CDMO industry is classified based on product type, therapeutic area, service type, end-user, and region.

The liquid formulation segment in the topical drugs CDMO market will experience a notable CAGR between 2024 and 2032. Liquid formulations offer advantages such as ease of application, faster absorption, and potential for precise dosing, making them preferred for various dermatological and cosmetic applications. This segment's growth is ushered by innovations in formulation techniques and increased consumer preference for liquid-based skincare products. Pharmaceutical companies are increasingly outsourcing liquid topical drug development and manufacturing to CDMOs to capitalize on their formulation development and regulatory compliance expertise, fueling market expansion in this specialized area.

The pain management segment will garner considerable topical drugs CDMO market share by 2032 because of the increasing prevalence of chronic pain conditions globally. Topical formulations offer non-invasive and localized pain relief, preferred by patients seeking alternatives to oral medications. This trend is supported by advancements in transdermal delivery technologies, enhancing the efficacy and safety profiles of topical pain treatments. Pharmaceutical companies are leveraging CDMOs' specialized capabilities in formulation development and manufacturing to meet the rising demand for innovative topical pain management solutions, driving expansion in this specialized market segment.

Asia Pacific topical drugs CDMO market size will exhibit a significant CAGR during the forecast period. Rising healthcare expenditure, increasing prevalence of chronic skin conditions, and expanding pharmaceutical markets are driving growth. Asia Pacific's large population and improved healthcare infrastructure and regulatory reforms foster opportunities for CDMOs. Companies are increasingly outsourcing topical drug development and manufacturing to capitalize on the region's skilled workforce and cost-effective manufacturing capabilities. As Asia Pacific continues to emerge as a hub for pharmaceutical innovation and production, the demand for specialized CDMO services in topical drugs is expected to rise significantly.

Product Code: 9137

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing demand for topical medications
  - 3.2.1.2 Growing adoption of outsourcing of manufacturing activities
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Challenges in quality control
  - 3.2.2.2 High capital investment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Semi-solid formulations
- 5.2.1 Creams
- 5.2.2 Ointments
- 5.2.3 Gels
- 5.2.4 Other semi-solid formulations
5.3 Liquid formulation
5.4 Trans dermal products
5.5 Solid formulations

Chapter 6 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Dermatology
6.3 Pain management
6.4 Wound care
6.5 Ophthalmology
6.6 Other therapeutic areas

Chapter 7 Market Estimates and Forecast, By Service Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Contract manufacturing
7.3 Contract development

Chapter 8 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Pharmaceutical companies
8.3 Biotechnology companies
8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

10.1 Ascendia Pharmaceuticals
10.2 Bora Pharmaceutical CDMO
10.3 Cambrex Corporation
10.4 Contract Pharmaceuticals Limited
10.5 DPT Laboratories, Ltd.
10.6 The Lubrizol Corporation
10.7 MedPharm Ltd
10.8 PCI Pharma Services
10.9 Pierre Fabre Group
10.10 Piramal Pharma Solutions